ArticleFrontiers in toxicology2026
Oridonin attenuates diclofenac-induced organ damage by suppressing endoplasmic reticulum stress and inflammasome activation.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) extensively prescribed in clinical practice; its use can be associated with toxic effects on multiple organs. These deleterious effects are associated with a combination of oxidative stress, sterile inflammation, and disrupted epithelial barrier integrity. Oridonin has strong antioxidant and anti-inflammatory characteristics, making it a potential candidate for NSAID-induced organ damage. Objective: Evaluate the protective effects of oridonin against diclofenac-induced liver, kidney and stomach toxicity, while elucidating molecular mechanisms involved in oxidative stress modulation, endoplasmic reticulum (ER) stress suppression, inflammasome inhibition and barrier preservation of epithelial cells. Methods: 30 male Sprague-Dawley rats were divided into five groups: normal control, oridonin control, diclofenac (100 mg/kg, IP), and diclofenac treated with low-dose (10 mg/kg) or high-dose (20 mg/kg) oridonin were the experimental conditions. Renal and hepatic function was assessed by serum and urinary markers. Oxidative stress was assessed by the determination of MDA, GSH, and total antioxidant capacity (TAC) in tissue homogenates. Molecular pathways were studied by ELISA and Western blotting to quantify ER stress markers (IRE1, CHOP, PERK) and the TXNIP/NLRP3/Caspase-1 inflammasome axis. Gastric barrier integrity was confirmed by expression measurement of tight junction proteins (Claudin, ZO-1, Occludin), histopathological, and immunohistochemical markers of NF-κB and IL-1β. Results: Oridonin pretreatment led to the recovery of antioxidant defenses and large decreases in the activation of the TXNIP/NLRP3/Caspase-1 axis, and ER stress signaling. In addition, oridonin maintained the gastric mucosal architecture and the expression of critical tight junction proteins and inhibited NF-κB-induced inflammation. Conclusion: Oridonin ameliorates diclofenac-induced multi-organ toxicity by reducing oxidative stress and ER stress, inhibiting the NLRP3 inflammasome, and preserving epithelial barrier integrity. Thus, oridonin can be considered a suitable drug to ameliorate the unwanted side effects of NSAID treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.